<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855760</url>
  </required_header>
  <id_info>
    <org_study_id>REL-1017-310</org_study_id>
    <nct_id>NCT04855760</nct_id>
  </id_info>
  <brief_title>Open Label Study to Assess the Safety of REL-1017 for Major Depressive Disorder</brief_title>
  <acronym>RELIANCE-OLS</acronym>
  <official_title>A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relmada Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relmada Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 1-year open-label study to access the safety of REL-1017 once daily (QD) as an&#xD;
      adjunctive treatment of Major Depressive Disorder. Study participants will continue to take&#xD;
      their current antidepressant therapy in addition to the study drug for the duration of the&#xD;
      treatment period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of REL-1017 as incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>REL-1017 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take 1 tablet of REL-1017 25 mg, orally, per day in addition to their ongoing antidepressant (ADT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REL-1017</intervention_name>
    <description>REL-1017 tablet</description>
    <arm_group_label>REL-1017 25 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults 18 to 65 years, inclusive.&#xD;
&#xD;
          -  Diagnosed with Major Depressive Disorder (MDD) based on Structured Clinical Interview&#xD;
             for DSM-5 (SCID-5) for MDD.&#xD;
&#xD;
          -  Current major depressive episode.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any current and primary psychiatric disorder other than Major Depressive Disorder.&#xD;
&#xD;
          -  Severe alcohol or substance use disorder.&#xD;
&#xD;
          -  History of bipolar I and II disorder, psychosis, and/or mania.&#xD;
&#xD;
          -  Acute or chronic condition that, in the Investigator's opinion, would limit the&#xD;
             subject's ability to complete or participate in this clinical study.&#xD;
&#xD;
          -  Prior participation in a ketamine, esketamine, dextromethorphan or any other NMDAR-&#xD;
             antagonist study, or received esketamine at any time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Pappagallo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Relmada Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Director</last_name>
    <phone>(332) 900-5901</phone>
    <email>clinicaltrials@relmada.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Relmada Site 117</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Relmada Site 122</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>REL-1017</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

